Free tool
Drug Trial Radar: Respiratory
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
890
Completed, industry sponsors, Respiratory, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed890
890 trials
Showing 1 to 25, recently updated first.
Hanlim Pharm. Co., Ltd.Industry
NCT06434792 · 95 participants · Start May 18, 2023 · Primary completion Aug 27, 2024
Drug: Bronpass Tab. · For: Chronic Obstructive Pulmonary Disease
Sites: Seoul, South Korea
SPARK BiopharmaIndustry
NCT06747923 · 32 participants · Start Jan 27, 2025 · Primary completion Jul 21, 2026
Drug: SB17170; Placebo · For: IPF; Idiopathic Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis (IPF)
Sites: Goyang, South Korea; Gwangmyeong, South Korea; Seoul, South Korea · 5 sites in all
- A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)Pivotal-lookingCompleted
Endeavor Biomedicines, Inc.Industry
NCT06422884 · 213 participants · Start Nov 15, 2024 · Primary completion Aug 21, 2026
Drug: ENV-101; Placebo · For: Idiopathic Pulmonary Fibrosis; Progressive Fibrosing Interstitial Lung Disease
Sites: Quilmes, Argentina; Buenos Aires, Argentina; Mendoza, Argentina · 78 sites in all
- MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingCompleted
Syndax PharmaceuticalsIndustry
NCT06132256 · 145 participants · Start Dec 11, 2023 · Primary completion Aug 27, 2026
Drug: Axatilimab · For: Idiopathic Pulmonary Fibrosis
Sites: Camperdown, Australia; Birtinya, Australia; Brisbane, Australia · 78 sites in all
Ethris GmbHIndustry
NCT07059767 · 50 participants · Start Jun 24, 2025 · Primary completion Sep 1, 2026
Drug: ETH47; Placebo · For: Asthma (Diagnosis)
Sites: London, United Kingdom; Manchester, United Kingdom
Clarametyx Biosciences, Inc.Industry
NCT06159725 · 43 participants · Start Jun 24, 2024 · Primary completion Nov 14, 2025
Drug: CMTX-101; Placebo · For: Persistent Infection; Cystic Fibrosis
Sites: Birmingham, Alabama; Palo Alto, California; San Franciso, California · 23 sites in all
- A Study to Evaluate Solriktug in Adult Participants With AsthmaPivotal-lookingCompleted
Uniquity One (UNI)Industry
NCT06496607 · 145 participants · Start Jul 26, 2024 · Primary completion Jul 6, 2026
Drug: NSI-8226; NSI-8226 and 2 more · For: Asthma
Sites: Mobile, Alabama; Peoria, Arizona; Encinitas, California · 69 sites in all
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With BronchiectasisPivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT06166056 · 108 participants · Start Nov 29, 2023 · Primary completion Aug 27, 2026
Drug: CHF6333; CHF6333 Placebo · For: Bronchiectasis
Sites: Cambridge, United Kingdom; Dundee, United Kingdom; Edinburgh, United Kingdom · 8 sites in all
- A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT05037929 · 1,334 participants · Start Oct 5, 2021 · Primary completion Feb 24, 2025
Drug: Astegolimab; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Dothan, Alabama; Jasper, Alabama; Mobile, Alabama · 193 sites in all
- A Trial of SHR-1905 in Subjects With Severe Uncontrolled AsthmaPivotal-lookingCompleted
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT05593250 · 260 participants · Start Jan 17, 2023 · Primary completion Dec 5, 2025
Drug: SHR-1905; placebo · For: Asthma
Sites: Guangzhou, China
- A Phase 2 Trial of JKN24011 in COPDPivotal-lookingCompleted
Joincare Pharmaceutical Group Industry Co., LtdIndustry
NCT07440524 · 215 participants · Start Aug 1, 2024 · Primary completion Apr 2, 2026
Drug: JKN24011 · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Shanghai, China
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05668741 · 26 participants · Start Feb 27, 2023 · Primary completion Apr 21, 2026
Drug: VX-522 mRNA therapy; IVA · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Long Beach, California; Palo Alto, California · 26 sites in all
- A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis BronchiectasisPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT06280391 · 314 participants · Start Feb 20, 2024 · Primary completion Sep 16, 2025
Drug: Itepekimab (SAR440340); Placebo · For: Bronchiectasis
Sites: Phoenix, Arizona; Los Angeles, California; Westminster, California · 117 sites in all
Regend TherapeuticsIndustry
NCT05638776 · 58 participants · Start Dec 6, 2022 · Primary completion Jul 9, 2025
Drug: REGEND001 cell therapy; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 8 sites in all
Zambon SpAIndustry
NCT02227394 · 20 participants · Start Aug 2014 · Primary completion Nov 2014
Drug: Z7200; Symbicort® Turbohaler® · For: Asthma; Asthma Chronic; Asthma Bronchial and 1 more
Sites: Edegem, Belgium
- Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)Pivotal-lookingCompleted
Connect Biopharm LLCIndustry
NCT06940154 · 159 participants · Start Aug 12, 2025 · Primary completion Jul 30, 2026
Drug: Matching placebo in prefilled syringe · For: COPD Acute Exacerbation
Sites: Birmingham, Alabama; Palo Alto, California; Valencia, California · 52 sites in all
- Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)Pivotal-lookingCompleted
Connect Biopharm LLCIndustry
NCT06940141 · 160 participants · Start Aug 8, 2025 · Primary completion Jul 17, 2026
Drug: Matching placebo in prefilled syringe · For: Asthma Acute
Sites: Palo Alto, California; Valencia, California; Wilmington, Delaware · 58 sites in all
- Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)Pivotal-lookingCompleted
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAIndustry
NCT07016412 · 497 participants · Start Jul 31, 2025 · Primary completion Aug 17, 2026
Drug: Ensifentrine 3 mg; Glycopyrrolate 21.25 mcg and 2 more · For: Chronic Obstructive Pulmonary Disease
Sites: Dothan, Alabama; Phoenix, Arizona; Tucson, Arizona · 57 sites in all
- A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02546700 · 309 participants · Start Sep 17, 2015 · Primary completion Nov 25, 2016
Drug: Lebrikizumab; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Birmingham, Alabama; Northridge, California; Palm Springs, California · 63 sites in all
Sionna Therapeutics Inc.Industry
NCT07108153 · 15 participants · Start Nov 3, 2025 · Primary completion Jun 25, 2026
Drug: SION-719; Placebo-to-match SION-719 · For: Cystic Fibrosis (CF)
Sites: Denver, Colorado; Iowa City, Iowa; Baltimore, Maryland · 13 sites in all
- Efficacy and Safety of CP006 Inhalation Powder in Participants With AsthmaPivotal-lookingCompleted
Shanghai Xin Huanghe Pharmaceutical Co., Ltd.Industry
NCT07807007 · 150 participants · Start Nov 21, 2025 · Primary completion Aug 3, 2026
Drug: Budesonide, Formoterol Fumarate, and Umeclidinium Bromide; Budesonide, Formoterol Fumarate, and Umeclidinium Bromide and 4 more · For: Asthma
Sites: Hefei, China; Beijing, China; Chongqing, China · 13 sites in all
SanofiSanofi (SNY)
NCT05326412 · 49 participants · Start May 19, 2022 · Primary completion Mar 5, 2025
Drug: Itepekimab SAR440340 · For: Chronic Obstructive Pulmonary Disease
Sites: Torrance, California; Denver, Colorado; Miami, Florida · 23 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT06241560 · 20 participants · Start Mar 5, 2026 · Primary completion Aug 5, 2026
Drug: BI 1015550; Pirfenidone · For: Idiopathic Pulmonary Fibrosis
Sites: The Woodlands, Texas; Tbilisi, Georgia · 3 sites in all
PfizerPfizer (PFE)
NCT06137742 · 97 participants · Start Nov 17, 2023 · Primary completion Jul 31, 2026
Drug: PF-07868489; Placebo for PF-07868489 · For: Pulmonary Arterial Hypertension
Sites: Anaheim, California; Costa Mesa, California; Orange, California · 46 sites in all
- Study of TTI-101 in Participants With Idiopathic Pulmonary FibrosisPivotal-lookingCompleted
Tvardi Therapeutics, IncorporatedIndustry
NCT05671835 · 100 participants · Start May 15, 2023 · Primary completion Aug 14, 2025
Drug: TTI-101; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Birmingham, Alabama; La Jolla, California; Orange, California · 28 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.